A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Crovalimab (Primary) ; Crovalimab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Registrational; Therapeutic Use
- Acronyms COMMUTE-p
- Sponsors Roche
- 13 Aug 2024 Planned End Date changed from 16 Sep 2029 to 20 Sep 2029.
- 16 Jun 2023 Planned number of patients changed from 35 to 45.
- 23 Aug 2022 Planned End Date changed from 16 Mar 2029 to 16 Sep 2029.